))
The changing landscape of drug clinical assessment: Tommy Bramley on the JCA
Manage episode 490763233 series 3079777
Content provided by pharmaphorum. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by pharmaphorum or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://ppacc.player.fm/legal.
The JCA process was passed into law by the European Union in 2022. The Joint Clinical Assessment is a process that will systematically assess all available clinical evidence for new drugs. Rolled out in stages, starting with oncology drugs and advanced therapy medicinal products this year, it will be fully implemented by 2030.
In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Tommy Bramley, SVP of market access and healthcare consulting at Cencora, about the JCA, as yet unanswered questions (at the time of the conversation) and the key challenges facing manufacturers.
Bramley also discusses the work of Cencora within this changing landscape of drug clinical assessment.
You can also listen to episode 187a of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series – on Apple Podcasts, Spotify, Overcast, Pocket Casts, Podbean, and pretty much wherever else you download your other podcasts from.
253 episodes
Share
